1.
Clin Case Rep
; 6(4): 698-701, 2018 04.
Artículo
en Inglés
| MEDLINE
| ID: mdl-29636943
RESUMEN
Patients presenting with an acute ischemic stroke despite dabigatran therapy (last intake <24 h or unknown) should be evaluated for reversal by idarucizumab, making them eligible for safe and effective intravenous thrombolysis. It has been shown to be feasible, well-tolerated, and easy to manage in an emergency room or stroke unit.
2.
Acta Neurol Belg
; 117(4): 951-952, 2017 12.
Artículo
en Inglés
| MEDLINE
| ID: mdl-28653094